Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma.

ABSTRACT:

Objective

Lung cancer is one of the deadliest malignancies. The immune checkpoint-blockade (ICB) tumor therapy has led to striking improvement of long-term survival for some lung cancer patients. However, the response rate of immunotherapy is still low for lung cancer. Studying the tumor microenvironment (TME) should shed light on improvement of immunotherapy of lung cancer. Interleukin-33 (IL-33), an "alarmin" cytokine, has been implicated in tumor associated immune responses and inflammatory diseases of the lung. The role of IL-33 in lung cancer progression, however, remains elusive. This study is designed to characterize IL-33 expression in lung tumor tissues and establish the clinical significance of IL-33 in non-small cell lung cancer lung cancer (NSCLC).

Materials and meth

SUBMITTER: Yang M 

PROVIDER: S-EPMC5834175 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature